NITROSAMINES RISK ELECTRONIC SUBMISSION FORM

INSTRUCTIONS TO APPLICANTS

INFARMED, I.P - DAM







MAH RESPONSABILITIES

TAKING INTO ACCOUNT THEIR KNOWLEDGE OF THE MANUFACTURING PROCESSES AS WELL AS THE POTENTIAL SOURCES OF NITROSAMINE IMPURITIES, MAHs SHOULD WORK WITH MANUFACTURERS OF API AND FINISHED PRODUCTS IN ORDER TO REVIEW THE API AND FINISHED PRODUCT MANUFACTURING PROCESSES WITH RESPECT TO THE ARRANGEMENTS FOR PREVENTING NITROSAMINE FORMATION AS WELL AS CONTAMINATION OR CROSS-CONTAMINATION

STEP 1 RISK EVALUATION: MAHs should perform risk evaluation of their medicinal products containing chemically synthesised API.

STEP 2 CONFIRMATORY TESTING: in the event that a risk of presence of nitrosamines is identified as a result of the risk evaluation, confirmatory testing should be carried out using appropriately validated and sensitive methods in accordance with the prioritisation deriving from the risk evaluation conducted in step 1.

STEP 3 CHANGES TO THE MARKETING AUTHORISATION: MAHs should apply for a variation in a timely manner to introduce any required changes, such as amendment of the manufacturing process or changes to product specifications.

INFARMED, I.P.

An electronic form was developed using SMUH-ALTER (national application for submission of Variation), where The MAH directly submits the results of its analysis and nitrosamine risk.

SMUH-ALTER – HOW TO USE THE SUBMISSION FORM?

TO START THE REGISTRATION CLICK ON THE BUTTON"NITROSAMINE RISK ASSESSMENT"

on12 g authorisation holder: Bayer Portugal, S.A.					
g authorisation holder: bayer Portugal, S.A.				Change Password	Logou
uments (SmPC & PIL)					Alerts (82
	Crea	ate New Application Marketing Authorizat	ion 🗸		
				Nitrosamine Risk	Assessment
		VARIATION APPLICATIONS			
Name of the medicinal product	Submissi	on Date	Procedure Number	MRP/National variation number	
	From To				Clear
Procedure Status	(yyyy-mm-dd) Fee St	tatus	Payment Form	Authorisation Type	
	✓ Any	~		Marketing Authorization	~
Application Type	Variatio	n Type	Variation		
	✓ Any	~			
d to submission list					
		List of Applications to subm	at		
				Create Proposal of payment form & Submit	Clear List
				and a second of the second	

TO SUBMIT THE RISK ANALYSIS, CLICK ON THE BUTTON"SUBMIT NITROSAMINE ANALYSIS RISK"

nLogin 🖲 Login 🖲 abouttabs 🇥 Redmine					
	Nitrosamine Ri	sk Assessment			
Name of the medicinal product	INN	Pharmaceutical Form		Strength	
Risk	Analysis Scheduled Date	Analysis Result			
			✓ Clear	Search	
	و ــــــــــــــــــــــــــــــــــــ			Submit Nitrosamine Analysis Ris	k
	Ва	ck			
name teter/muk alter aug/size Dafaultary					

IF YOU WANT TO SUBMIT RISK ANALYSIS TO "NO"

1. Click on "No"

(2) (2) (2) (3) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4	-testes/smuh alter gwp/risco/formSubmissaoRisco.aspx		- C Procurar.		×
🧔 formSubmissaoP	×			1 00 M W	- I
🖕 🖲 frmLogin	abouttabs 🗥 Redmine				
	Nitr	rosamine Risk Assessment			1.
Risk?					1
U Yes U No					1
		Back			
					\sim
	e é 🌢 C 🔯 🕫 🖻 🖻			s ⁴ ^ 🖸 🖬 🖓 👘 1732	
				30/01/2020	9

2. It is always necessary to include a search criteria

Then click on"Search"

http://www.com.com/com.com/com/com/com/com/com/com/com/com/com/						
Intp://iis-interno-testes/smon_anter_gwp/risco/romiscoir	nissaoRisco.aspx	- 0	Procurar			. ○ · ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
ubmissaoRisco × 🗋						
nLogin 🖲 Login 🕘 abouttabs 🧥 Redmine						
	Nitrosamine Ris	sk Assessment				
No						
	List Of Hedicia J Pr	educte Concerned				
	List of medicinal P					
Name of the medicinal product	INN	Pharmaceutical Form			Strengt	
Pick	Analysis Scheduled Date	Analysis Result				
	~)	, and the factor	~	Clear	Search	
	1)					
	Bad	ck .				
	Bad	×				
우 바 원 🔒 🍏 〇 🎟	• • •				e ^p ∧ ⊠∎	g (n. 1733 1 ⊈ (n. 1733)

IF YOU WANT TO SUBMIT RISK ANALYSIS TO "NO"

3. After the search, click on the button "Submit" in the line corresponding to the medicinal product for which the risk analysis is to be submitted

Manifestia (B) Lania (B) L	A Deductor								
frmLogin 🛃 Login 🛃 abouttai	DS • Reamine								
			Nitrosamine Ri	k Assessment					
lisk?									
)Yes ⊙No									
			List Of Medicinal Pr	oducts Concerned					
		1	List of medicinal P						
Name of the med	ncinal product		INN	Pharmaceut	ical Form			Strength	
/ Dir	L.	Analy	rir Schodulad Data	Analysis	Popult				
KIS	~	Analy		Analysis	Nesuli	~	Clear	Search	
		<u> </u>							
N		NN.		0/II					Su
Name or the medicinal	Devamethaso	ne + Clotrimazole	Cream	0.4 ma/a + 10 ma/a	No	Analysis	chequied Date	Analysis Re	Submit
Becozivme Forte	Vitamin B con	iplex + Biotin	Coated tablet	Associação	No				Submit
Svnera	Ethinylestradio	al + Gestodene	Coated tablet	0.03 ma + 0.075 ma	No	_			Submit
Progyluton	Norgestrel + E	stradiol valerate	Coated tablet	(0.5 mg + 2 mg) + (2 mg)					Submit
Previous Page Next Page >									
			Bad	.k					

IF YOU WANT TO SUBMIT RISK ANALYSIS TO "YES"

1. Click on "YES"

					- 0 ×
(a)	missaoRisco.aspx	- C Procurar			P - 🔐 🔆 😳
formSubm to × 🗈					
abouttabs 🔨 Redmine					
Rick	Nitrosamine Ri	sk Assessment			
●Yes ○No					
	List Of Medicinal Pr	roducts Concerned			
Name of the medicinal product	INN	Pharmaceutical Form		Strength	
Pisk	Analysis Scheduled Date	Analysis Result			
			Clear	Search	
	[(L			
	Ba	ck			
					1740

2. Then click the button "Edit" to have access to the medicinal product sheet

			Nitrosamine Risk Assess	ment					
dsk? €Yes ○No									
			List Of Medicinal Products O	oncerned					
Name of the medicinal	product	INN		Pharmaceutical	Form			Strength	
a									
Risk		Analysis Sched	Juled Date	Analysis Resu	IIT		Close	Form	`
			•)			*	Citidal	Search	
Name of the medicinal prod	lict	INN	Pharmaceutical Form	Strength	Risk	Analysis S	cheduled Date	Analys	is Result
spirina Microactive	Acetylsalicylic	acid	Coated tablet	500 mg	Yes	1 year to 1,5 year	ars	_	Edit
sprina Mile	Acetyisalicylic	acid	Coated tablet	1000 mg	Tes	30 meses a 3 ar	105		Edit
ano-canesten i	Lannazae		Vaginai capsure, soir	500 mg	NO	Listil & months	_	Nitros ominos dot	ected Edit
Weena (F600260.)	Levonoigestrei		Calution for injustion	19.5 mg	TUS	Until 6 months	_	Nurdsamines det	ected Edit
otagraf (5699203,)	Meglumine gat	Interate	Solution for injection	279.32 mg/mi	Vec	1 verto 15 ver	200	Nitros aminos dot	ected Edit
spirina Complex	Acotylsalicylin	acid + Pseudoenhedrine	Granulos for oral suspension	500 ma + 30 ma	Yes	1 year to 15 year	ars	Nitrosaminos dot	ected Edit
spirina C	Acetylsalicylic	acid + Ascorbic acid	Effervescent tablet	800 mg + 480 mg	Yes	Until 6 months		No Nitrosamines	detected Edit
Previous Page Next Page >									
			Back						

In the field "Analysis Scheduled Date" the proposed time for carrying out the confirmatory test must be selected. Click on "Submit".



In the field "Analysis Result" select the final result after the confirmatory test.

Select No Nitrosamines detected or Nitrosamines detected

The http://iis-interno-testes/smub a	er owo/risco/Detalhes.asox?D=593221	* C Procurar	0.0
talhes × 🖸			e
frmLogin Dogin abouttabs	ine		
	r		
	Description		
	Não Comercializado	^	
		Ť	
	Attached Documents (Max: 10 MB)		
	File Name		
em por	Download		
Delete Document			
Analysis Scheduled Da	~		
na raisa a			
Analysis Result			
No Nitrosamines detected			
Ntrosamines detected			
	Nitrosamine Concentration		
		~	
		~	
	L		
	Back , Submit		
	DOCK South		
- O HL 🔿 🗹			8 ^ 🛐 🖬 🗔 40 1755

MEDICINAL PRODUCT SHEET- RISK ANALYSIS TO "YES" when in the field "Analysis Result" has been selected as the final result of the confirmatory test - Nitrosamines detected

Must be included in the field "Nitrosamine concentration", information regarding the level of nitrosamines detected, copying in full the sentence corresponds to the applicable scenario: • Scenario A - exceeding the AI or exceeding the lifetime excess cancer risk of 1:100,000

• Scenario B - not exceeding the AI or the lifetime excess cancer risk of 1:100,000 but its content is above 10% the AI

In this case, must also be indicated, the purpose of the variation and expected date of submission.

• Scenario C - is consistently below 10% of the AI or the risk level of 1:100,000

CLICK ON "SUBMIT"

Detalhes × C				
🕘 frmLogin 🕘 Login 🕘 abouttabs 🔨 Redmine				
		Decembring		
	Não Comercializado	Description		
			~	
			~	
	L			
	File Name	Attached Documents (Max: 10 MB)		
n pdf	The Name	Download		
unalysis Scheduled Date]			
nalucie Decult		· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·	
unity is result.			insert	sentence
No Nitrosamines detected Nitrosamines detected				oontonoo
			/ type/in	formation
		Nitrosamine Concentration	regar	ding the
			/ Tegai	unguie
			app	licable
				pario
			SCE	enano

when in the field "Analysis Result" has beeen selected as the final result of the confirmatory test - Nitrosamines detected, the templates available on the <u>CMDh website</u>, must be attached to the SMUH-ALTER.

It is possible to upload many documents on the SMUH-ALTER platform. Although MAH does not view all documents, Infarmed is able to view them.

If new nitrosamines are detected (Scenario D) must also be include the information in the SMUH-ALTER plataform, in the field "Nitrosamine concentration", including the following sentence:

"New nitrosamina detected – Name of nitrosamine – Scenario proposed: A, B ou C", and attaching all expected supporting documentation:

1 - Template(s) available on the CMDh website

2 - All quality and toxicological documentation regarding step 2 of the procedure, namely (if applicable):

- Type of method used
- Detection and quantification limits (LoD, LoQ)
- Results of the analyzed batches
- Methods Validation
- SAR Evaluation assessment

In parallel, this situation must be communicated to the email pt_chmp_referrals@infarmed.pt.

CHANGE THE RISK ANALYSIS FROM "NO" TO "YES"

1. Click on "YES" and insert a search criteria for the medicinal product that is necessary to change the risk. Then click on "Search"

	Nitrosamin	e Risk Assessment		
6				
	List Of Medicin	al Products Concerned		
Name of the medicinal product	INN	Pharmaceutical Form	27	
Reb	An along Pakash dad Pasa	Analysis Preside		
- Nuk		~	V Clear Search	
		Back		
		Back		
		Back		
		Bex		
		Box		
		Bec		
		<u>Inc</u>		

2. Click on "Edit" in the line of the medicinal product to be changed and you will have access to the medicinal product sheet



3. In the field "Analysis Scheduled Date" the proposed time for carrying out the confirmatory test must be selected. Click on "Submit".

The risk will become YES



RISK ANALYSIS "NO" BECAUSE THE MEDICINAL PRODUCT IS NOT MARKETED

Submit the risk "NO". Then access the medicinal product sheet as if it were a submission "YES" and in the field "DESCRIPTION" write "NOT MARKETED".

frmLogin 🖲 Login 🕘 abouttabs 🗥 Redmine			
		· · · ·	
	Des	cription	
	Não Comercializado	^	
		~	
	File Name	nents (max: 10 mb)	
dt		Download	
elete Document			
outo Documum			
lysis Scheduled Date			
	1		
lysis Result	I		
lysis Result			
lysis Result			
ysis Result 🗸 🗸	Nitrosamine	€ Concentration	
ysis Result	Nitrosamine	≥ Concentration	
ysis Result	Nitrosamine	€ Concentration	
lysis Result	Nitrosamine	₽ Concentration	









